EU approves Enhertu plus pertuzumab for HER2+ metastatic breast cancer
The EU has approved Enhertu plus pertuzumab as a new first-line regimen for patients with HER2-positive metastatic breast cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.